ET743 treated bladder cancer for proteomics sequencing
收藏integrated proteome resources2026-02-07 收录
官方服务：
资源简介：
ET743 treated bladder cancer for proteomics sequencing
应用场景：
创建时间：
2025-01-21
相关数据集
Table_1_PUF60/AURKA Axis Contributes to Tumor Progression and Malignant Phenotypes in Bladder Cancer.XLSX
Abnormal expression or mutation of RNA splicing proteins are widely observed in human cancers. Here, we identified poly(U) binding splicing factor 60 (PUF60) as one of the most differentially expresse
NIAID Data Ecosystem60
Correlation of histopathologic characteristics to protein expression and function in malignant melanoma
Background Metastatic melanoma is still one of the most prevalent skin cancers, which upon progression has neither a prognostic marker nor a specific and lasting treatment. Proteomic analysis is a ver
NIAID Data Ecosystem40
Table5_4-Methoxydalbergione Inhibits Bladder Cancer Cell Growth via Inducing Autophagy and Inhibiting Akt/ERK Signaling Pathway.XLSX
Bladder cancer (BC) ranks the fourth in incidence in cancers of men and is a common malignant tumor in women. 4-Methoxydalbergione (4MOD), which is purified from Dalbergia sissoo Roxb, has been shown
NIAID Data Ecosystem30
Additional file 1 of Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment
Additional file 1: SI Materials 1. Antibodies used in DigiWest protein profiling analysis. Figure S1. Multicolor flow cytometry analysis of isolated and expanded TILs from BC specimen. Figure S2. Corr
NIAID Data Ecosystem40
Proteomic profiling of glioblastoma stem cells and their small extracellular vesicles
The heterogeneous nature of glioblastoma stem-like cells (GSCs) creates hurdles in developing effective therapies against glioblastoma, making it extremely difficult to eradicate. In this part of the
NIAID Data Ecosystem30
